Pfizer Inc. (NYSE:PFE) Shares Sold by Arvest Bank Trust Division

Arvest Bank Trust Division lowered its stake in Pfizer Inc. (NYSE:PFE) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 476,705 shares of the biopharmaceutical company’s stock after selling 8,438 shares during the period. Arvest Bank Trust Division’s holdings in Pfizer were worth $12,647,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on PFE. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 8th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Price Performance

Pfizer stock opened at $22.05 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company’s 50 day simple moving average is $25.02 and its 200-day simple moving average is $26.28. The company has a market capitalization of $125.06 billion, a price-to-earnings ratio of 15.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.